NCT02238808View on ClinicalTrials.gov

A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

July 30, 2018

Study Completion Date

June 30, 2028

Conditions
Estrogen Receptor Positive Breast Cancer
Interventions
DRUG

Estradiol

Eligible participants will take 2 mg Estradiol 3 times daily for 7-14 days pre-surgery.

Trial Locations (1)

T6G 1Z2

Cross Cancer Institute, Edmonton

All Listed Sponsors
lead

AHS Cancer Control Alberta

OTHER

NCT02238808 - A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers | Biotech Hunter | Biotech Hunter